{"nctId":"NCT00287729","briefTitle":"Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","startDateStruct":{"date":"2006-04"},"conditions":["Idiopathic Pulmonary Fibrosis"],"count":344,"armGroups":[{"label":"2403 mg/day pirfenidone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pirfenidone"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Pirfenidone","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Primary Inclusion criteria:\n\n* diagnosis of idiopathic pulmonary fibrosis\n* 40 to 80 years of age\n* Forced Vital Capacity ≥ 50% predicted value\n* carbon monoxide diffusing capacity (DLco) ≥ 35% predicted value\n* either Forced Vital Capacity or carbon monoxide diffusing capacity (DLco) ≤ 90% predicted value\n* no improvement in past year\n* able to walk 150 meters in 6 minutes and maintain saturation ≥ 83% while on no more than 6 liters per minute supplemental oxygen\n\nPrimary Exclusion criteria:\n\n* unable to undergo pulmonary function testing\n* evidence of significant obstructive lung disease or airway hyper-responsiveness\n* in the clinical opinion of the investigator, the patient is expected to need and be eligible for a lung transplant within 72 weeks of randomization\n* active infection\n* liver disease\n* cancer or other medical condition likely to result in death within 2 years\n* diabetes\n* pregnancy or lactation\n* substance abuse\n* personal or family history of long QT syndrome\n* other IPF treatment\n* unable to take study medication\n* withdrawal from other IPF trials","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in Percent Predicted Forced Vital Capacity(FVC)","description":"Mean Change in Percent Predicted Forced Vital Capacity (FVC) as measured from baseline to week 72. It is calculated as the simple difference between baseline Percent Predicted FVC measurements and week 72 Percent Predicted FVC measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9","spread":"19.58"},{"groupId":"OG001","value":"-10","spread":"19.12"}]}]}]},{"type":"SECONDARY","title":"Categorical Assessment of Absolute Change in Percent Predicted Forced Vital Capacity","description":"Based on the change in baseline percent predicted FVC at week 72, patients were assigned to 1 of 5 categories: mild decline (\\<10% but \\>=0% decline), moderate decline (\\<20% but \\>=10% decline), severe decline (\\>=20% decline), mild improvement (\\>0% but \\<10% improvement), or moderate improvement (\\>=10% improvement). Those who died or had a lung transplant before Week 72 were included in the severe decline category. The results indicate the number of patients who experience Categorical Change in Percent Predicted Forced Vital Capacity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival","description":"Progression is defined as the first occurrence of a 10% absolute decline from baseline in percent predicted Forced Vital Capacity, a 15% absolute decline from baseline in percent predicted hemoglobin(Hgb)-corrected carbon monoxide diffusing capacity (DLco), or, death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Six-Minute Walk Test (6MWT) Distance","description":"The change from Baseline to week 72 in distance walked during the 6-Minute Walk Test. This measure was calculated as the simple difference between baseline distanced walked over 6 minutes and week 72 distance walked over 6 minutes as measured in meters (m).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45","spread":"140"},{"groupId":"OG001","value":"-77","spread":"128"}]}]}]},{"type":"SECONDARY","title":"Change in Worst Oxygen Saturation by Pulse Oximetry (SpO2) Measurement Observed During the 6-Minute Walk Test","description":"The change from baseline to week 72 in worst oxygen saturation during the 6-Minute Walk Test as measure by Pulse Oximetry (SpO2) Level. It is calculated as the simple difference between baseline SpO2 measurements and week 72 SpO2 measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"3.83"},{"groupId":"OG001","value":"-1.3","spread":"6.63"}]}]}]},{"type":"SECONDARY","title":"Change in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs","description":"The change from baseline to week 72 in Percent Predicted Hemoglobin (Hb)-Corrected Carbon Monoxide Diffusing Capacity (DLco) of the Lungs. It is calculated as the simple difference between baseline DLco measurements and week 72 DLco measurements.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8","spread":"12.61"},{"groupId":"OG001","value":"-9.2","spread":"13.24"}]}]}]},{"type":"SECONDARY","title":"Change in Dyspnea Score","description":"The mean change from baseline to week 72 in Dyspnea score was measured by the University of San Diego Shortness of Breath Questionnaire (UCSD SOBQ). The SOBQ is used to assess shortness of breath with various activities of daily living (for example, brushing ones teeth or mowing the lawn). Patients rated the severity of their shortness of breath experienced on an average day during the past week on a 6 point scale (0 to 5),with 0= not at all breathless, 4= severely breathless and 5= Maximally or unable to do because of breathlessness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"24.72"},{"groupId":"OG001","value":"13.9","spread":"27.89"}]}]}]},{"type":"SECONDARY","title":"Worsening of IPF","description":"Worsening of IPF was defined by the occurrence of any of the following events:\n\nAcute IPF exacerbation, IPF-related death, Lung transplantation, or Respiratory hospitalization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"146","spread":null},{"groupId":"OG001","value":"141","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":53,"n":171},"commonTop":["Cough","Rash","Idiopathic Pulmonary Fibrosis","Dyspnoea","Headache"]}}}